We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Therapy of Steroid-Resistant Inflammatory Bowel Disease.
- Authors
Manz, Michael; Vavricka, Stephan R.; Wanner, Roger; Lakatos, Peter L.; Rogler, Gerhard; Frei, Pascal; Safroneeva, Ekaterina; Schoepfer, Alain M.
- Abstract
Background and Aims: Although systemic corticosteroids are successfully administered for the induction of clinical response and remission in the majority of patients with inflammatory bowel disease (IBD) presenting with a flare, a proportion of these patients demonstrate a primary nonresponse to steroids or in the case of an initial response, they develop a resistance or a steroid dependence. Long-term therapy with corticosteroids for treatment of IBD should be avoided, given the high frequency of adverse treatment effects. Knowledge about treatment strategies in case of steroid nonresponse is therefore highly relevant. Methods: A systematic literature research was performed using Medline and Embase to summarize the currently recommended treatment strategies for steroid-resistant IBD. Results: Treatment of steroid-resistant Crohn's disease is based on the introduction of immunomodulators such as azathioprine, 6-mercaptopurine or methotrexate, the anti-TNF drugs infliximab, adalimumab and certolizumab pegol. In the case of steroid resistance in ulcerative colitis, aminosalicylates, the above-mentioned immunomodulators, infliximab, adalimumab or calcineurin inhibitors such as ciclosporin or tacrolimus may be administered. Conclusion: This review summarizes the current evidence for treating steroid-resistant IBD. Copyright © 2012 S. Karger AG, Basel
- Subjects
INFLAMMATORY bowel disease treatment; ADRENOCORTICAL hormones; COLITIS treatment; ULCERATIVE colitis; IMMUNOLOGICAL adjuvants
- Publication
Digestion, 2012, Vol 86, p11
- ISSN
0012-2823
- Publication type
Article
- DOI
10.1159/000341952